European Archives - Page 3 of 1370 - European Medical Journal

Data Support Outpatient Stem-Cell Mobilisation Safety

A real-world analysis suggests outpatient stem-cell mobilisation in multiple myeloma could safely reduce hospital admissions and bed use through risk stratification and machine learning prediction.

Vitamin K Antagonists Linked to Lower Short-Term Risk in COPD

Nationwide cohort data suggest vitamin K antagonists are linked to a lower 1-year risk of severe COPD exacerbation or death compared with DOACs.

Light-Triggered Microneedle Patch Aimed at IVF Injections

Light-triggered microneedle patch was tested to deliver IVF hormones on demand using near-infrared light, potentially reducing daily injection burden.

Emerging Prostate Cancer Diagnostics: Hashim Ahmed

Emerging Prostate Cancer Diagnostics: Hashim Ahmed. Chair and Professor of Urology, Imperial College London, UK..

The first and only approved dual inhibitor of IL-17A and IL-17F1-6

BIMZELX® Demonstrated Deep and Sustained Efficacy to 3 Years Across Multiple Disease Domains of PsA and the Full axSpA Spectrum…

Onc Now: A Career at the Cutting Edge of Nuclear Medicine

Nuclear medicine has undergone extraordinary transformation over the past decades, and it continues to redefine how cancer is diagnosed and…

AI tool

AI Tool Guides Care for Cancer Heart Attacks

The newly developed AI tool, known as ONCO-ACS, was designed specifically to predict six-month mortality, major bleeding, and ischaemic events in patients with cancer and acute coronary syndrome.

Month in pharma news, explained

Month in pharma news, explained – January 2026

In this news roundup, take a look back at top moments from the pharmaceutical industry in January 2026.

Two people shaking hands

UK and Japan strengthen science and technology ties

The UK and Japanese governments have announced a sweeping pharmaceutical and technology partnership.

Topical Pumecitinib for Mild-to-Moderate Atopic Dermatitis - EMJ

Topical JAK Inhibitor Shows Promise for Atopic Dermatitis

A phase IIb trial demonstrates that topical pumecitinib 3% gel significantly improves mild-to-moderate atopic dermatitis, with twice-daily dosing showing superior efficacy.